Estrella Immunopharma Inc (ESLA) Stock AnalysisESLAEstrella Immunopharma Inc

Estrella Immunopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancers and autoimmune diseases. Its lead product candidate, EB103, utilizes Eureka's ARTEMIS technology to target CD19, a protein expressed on the surface of almost all B-cell leukemias and lymphomas. The Company is also developing EB104, which also utilizes Eureka's ARTEMIS technology to target not only CD19, but also CD22, a protein that, like CD19, is expressed on the surface of most B-cell malignancies. The Company is also collaborating with Imugene Limited and its product candidate, CF33-CD19t an oncolytic virus (CF33-CD19t), to research the use of EB103 in conjunction with CF33-CD19t to treat solid tumors. Its EB201 program, in preclinical development, is being explored as a potential therapeutic approach targeting Systemic Lupus Erythematosus (SLE). It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Estrella Immunopharma Inc is not a good buy right now due to its poor financial performance and negative technical indicators. The current price is $0.71, which is down 49.27% year-to-date. The RSI is at 28.555, indicating that the stock is oversold, but this could also suggest a continued downtrend. The company has reported consistent losses, with a net income of -2,306,339 USD in Q2 2026 and a forward P/E ratio of 0, indicating no expected earnings growth. The main risk is the significant decline in stock value, as it has dropped 34.10% over the past year.